Gao YH - Search Results

1

Clinical Characteristics and Prognosis of Pediatric Idiopathic Multicentric Castleman Disease.

Gao YH, Yao JF, Li SY, Dang Y, Xu HY, Zou T, Li J, Zhang L, Zhang R. Gao YH, et al. Am J Hematol. 2025 Jan 3. doi: 10.1002/ajh.27574. Online ahead of print. Am J Hematol. 2025. PMID: 39752292 No abstract available.

2

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.

Zhang L, Gao YH, Li SY, Zhao H, Zhang MY, Yu YY, Liu YT, Li J. Zhang L, et al. Among authors: gao yh. Int J Hematol. 2024 Jun;119(6):631-637. doi: 10.1007/s12185-024-03747-7. Epub 2024 Mar 28. Int J Hematol. 2024. PMID: 38546960 Clinical Trial.

3

Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report.

Gao YH, Duan MH, Li J, Zhang L. Gao YH, et al. Turk J Haematol. 2024 Mar 1;41(1):61-63. doi: 10.4274/tjh.galenos.2024.2023.0477. Epub 2024 Feb 15. Turk J Haematol. 2024. PMID: 38356196 Free PMC article. No abstract available.

4

Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.

Gao YH, Liu YT, Zhang MY, Li SY, Fajgenbaum DC, Zhang L, Li J. Gao YH, et al. Br J Haematol. 2024 May;204(5):1830-1837. doi: 10.1111/bjh.19334. Epub 2024 Feb 15. Br J Haematol. 2024. PMID: 38356434 Free PMC article.

5

Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study.

Liu YT, Gao YH, Zhao H, Zhang MY, Duan MH, Li J, Zhang L. Liu YT, et al. Among authors: gao yh. Ann Hematol. 2024 Oct;103(10):4223-4230. doi: 10.1007/s00277-024-05783-z. Epub 2024 May 1. Ann Hematol. 2024. PMID: 38691144

6

Successful treatment of relapsed idiopathic multicentric Castleman disease-idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report.

Gao YH, Duan MH, Li J, Zhang L. Gao YH, et al. Br J Haematol. 2024 Sep;205(3):1208-1211. doi: 10.1111/bjh.19596. Epub 2024 Jun 10. Br J Haematol. 2024. PMID: 38859582 No abstract available.

7

Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single-centre, retrospective study.

Gao YH, Li SY, Dang Y, Duan MH, Zhang L, Li J. Gao YH, et al. Br J Haematol. 2025 Jan;206(1):152-158. doi: 10.1111/bjh.19827. Epub 2024 Oct 15. Br J Haematol. 2025. PMID: 39406386

8

Rapid Relapse of Idiopathic Multicentric Castleman Disease After Siltuximab Discontinuation in a Case with Complete Remission for More Than 10 Years.

Gao YH, Li J, Zhang L. Gao YH, et al. Turk J Haematol. 2024 Dec 2;41(4):283-285. doi: 10.4274/tjh.galenos.2024.2024.0339. Epub 2024 Nov 6. Turk J Haematol. 2024. PMID: 39501708 Free PMC article. No abstract available.

9

[Research Advances in Pathogenesis of Idiopathic Multicentric Castleman Disease].

Gao YH, Li J, Zhang L. Gao YH, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2024 Oct;46(5):756-762. doi: 10.3881/j.issn.1000-503X.16008. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2024. PMID: 39502058 Free article. Review. Chinese.

10

Quality of life after idiopathic multicentric Castleman disease in China: a cross-sectional, multi-center survey of patient reported outcome and caregiver reported outcome.

Chen J, Zhang MY, Gao YH, Zhang L, Li J. Chen J, et al. Among authors: gao yh. Orphanet J Rare Dis. 2024 Dec 19;19(1):469. doi: 10.1186/s13023-024-03450-0. Orphanet J Rare Dis. 2024. PMID: 39702341 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

729 results

Search Page

Filters